Cargando…

A Phase I dose‐escalation study of DCLL9718S, an antibody‐drug conjugate targeting C‐type lectin‐like molecule‐1 (CLL‐1) in patients with acute myeloid leukemia

Detalles Bibliográficos
Autores principales:	Daver, Naval, Salhotra, Amandeep, Brandwein, Joseph M., Podoltsev, Nikolai A., Pollyea, Daniel A., Jurcic, Joseph G., Assouline, Sarit, Yee, Karen, Li, Mengsong, Pourmohamad, Tony, Samineni, Divya, Sumiyoshi, Teiko, Vaze, Anjali, Dere, Randall C., Ma, Connie, Cooper, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Correspondences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252033/ https://www.ncbi.nlm.nih.gov/pubmed/33617672 http://dx.doi.org/10.1002/ajh.26136

Ejemplares similares

Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia
por: Leipold, Douglas D., et al.
Publicado: (2018)

Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients
por: Ngai, Lok Lam, et al.
Publicado: (2021)

Response to COVID-19 Infection and Vaccination in the CLL Population: A Large Single-Center Experience
por: Coltoff, Alexander, et al.
Publicado: (2022)

Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2019)

New directions for emerging therapies in acute myeloid leukemia: the next chapter
por: Daver, Naval, et al.
Publicado: (2020)

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
por: Daver, Naval G., et al.
Publicado: (2023)

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL
por: Jain, Nitin, et al.
Publicado: (2022)

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
por: Seymour, John F., et al.
Publicado: (2022)

The changing face of acute myeloid leukemia therapeutics in the elderly population
por: Daver, Naval, et al.
Publicado: (2015)

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies
por: Thompson, Philip A., et al.
Publicado: (2018)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Leptomeningeal involvement in CLL
por: Chantepie, Sylvain P., et al.
Publicado: (2014)

Not all lymphoid aggregates in chronic lymphocytic leukemia (CLL) patients are due to CLL!
por: Mahapatra, Lily, et al.
Publicado: (2021)

Poster: CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

CLL-IPI applied in Binet A CLL: a nationwide cohort study
por: Rotbain, Emelie C., et al.
Publicado: (2022)

Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021)

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
por: Daver, Naval, et al.
Publicado: (2021)

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018)

Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells
por: Chowdhury, Subir Roy, et al.
Publicado: (2021)

Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL
por: Collins, McKensie A., et al.
Publicado: (2022)

Significance of t (8: 14) in CLL?
por: Lakshmaiah, K. C., et al.
Publicado: (2010)

CLL kinetics in the tumor microenvironment
por: Sun, Clare, et al.
Publicado: (2017)

Tumor suppressors revival in CLL
por: Carrà, Giovanna, et al.
Publicado: (2017)

CLL und Covid-19
por: Behrend, Christian
Publicado: (2022)

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2021)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial
por: Samineni, Divya, et al.
Publicado: (2022)

Identification of CD105 (endoglin) as novel risk marker in CLL
por: Greiner, Sarah M., et al.
Publicado: (2022)

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
por: Kater, Arnon, et al.
Publicado: (2023)

Role of Radiation Based Conditioning Regimens in Patients With High-Risk AML Undergoing Allogenic Transplantation in Remission or Active Disease and Mechanisms of Post-Transplant Relapse
por: Salhotra, Amandeep, et al.
Publicado: (2022)

Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC
por: Decker, William K., et al.
Publicado: (2012)

Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL
por: Heyman, B, et al.
Publicado: (2016)

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
por: Parikh, Sameer A., et al.
Publicado: (2021)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

Primary gastric chorioadenocarcinoma: a needle in a haystack
por: Shastri, Aditi, et al.
Publicado: (2011)

T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
por: Daver, Naval, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0okpbd5n9po6b03et8vurticqn